Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2016

01-04-2016 | Letter to the Editor

Solitary plasmablastic lymphoma in the esophagus

Authors: Keichiro Mihara, Naomi Sasaki, Ooeda Mamoru, Masayuki Kanbe, Tatsuo Ichinohe, Shinichi Suehiro

Published in: Annals of Hematology | Issue 5/2016

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Swerdlow SH, Campo E, Harris NL et al (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon
2.
3.
Castillo JJ, Winer ES, Stachurski D et al (2011) HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk 11(2):185–189CrossRefPubMed
4.
O’Malley DP, Goldstein NS, Banks PM (2014) The recognition and classification of lymphoproliferative disorders of the gut. Hum Pathol 45(5):899–916CrossRefPubMed
5.
Castillo JJ, Reagan JL (2011) Plasmablastic lymphoma: a systematic review. ScientificWorldJournal 11:687–696CrossRefPubMed
6.
Liu JJ, Zhang L, Ayala E et al (2011) Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res 35(12):1571–1577CrossRefPubMed
7.
Castillo JJ, Bibas M, Miranda RN (2015) The biology and treatment of plasmablastic lymphoma. Blood 125(15):2323–2330CrossRefPubMed
8.
9.
Pinnix CC, Shah JJ, Chuang H et al (2015) Doxorubicin-based chemotherapy and radiation therapy produces favorable outcomes in limited-stage plasmablastic lymphoma: a single-institution review. Clin Lymphoma Myeloma Leuk. doi:10.​1016/​j.​clml.​2015.​12.​008
Metadata
Title
Solitary plasmablastic lymphoma in the esophagus
Authors
Keichiro Mihara
Naomi Sasaki
Ooeda Mamoru
Masayuki Kanbe
Tatsuo Ichinohe
Shinichi Suehiro
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2626-x

Other articles of this Issue 5/2016

Annals of Hematology 5/2016 Go to the issue

Review Article

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)

Original Article

Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia

Original Article

Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy

Original Article

Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults

Original Article

A comprehensive approach to the prevention of central venous catheter complications: results of 10-year prospective surveillance in pediatric hematology-oncology patients

Review Article

Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits